Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 9.22% is 32% below its 5-year average of 13.52%, near the low end of its 5-year range (8.27%–35.07%).
5.46% below its 12-month average of 9.75%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 10.70%.
GROSS MARGIN
9.22%
GROSS MARGIN AVG TTM
9.75%
GROSS MARGIN AVG 3Y
12.58%
GROSS MARGIN AVG 5Y
13.52%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-5.46%
CURRENT VS 3Y AVG
-26.71%
CURRENT VS 5Y AVG
-31.81%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
43.48%
median of 558 covered companies
CURRENT VS SECTOR MEDIAN
-78.80%
vs the sector median at left
Astrana Health, Inc.
Market Cap
$1.85B
Gross Margin
9.22%
TTM Avg
9.75%
3Y Avg
12.58%
5Y Avg
13.52%
Market Cap
$1.86B
Gross Margin
78.67%
TTM Avg
83.63%
3Y Avg
79.97%
5Y Avg
53.31%
Market Cap
$1.84B
Gross Margin
72.90%
TTM Avg
70.08%
3Y Avg
67.68%
5Y Avg
66.96%
Market Cap
$1.87B
Gross Margin
-319.36%
TTM Avg
-798.46%
3Y Avg
-813.46%
5Y Avg
-704.28%
Market Cap
$1.89B
Gross Margin
64.48%
TTM Avg
64.91%
3Y Avg
63.02%
5Y Avg
55.66%
Market Cap
$1.78B
Gross Margin
76.47%
TTM Avg
79.35%
3Y Avg
79.86%
5Y Avg
39.87%
Market Cap
$1.75B
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$1.95B
Gross Margin
70.49%
TTM Avg
67.64%
3Y Avg
66.50%
5Y Avg
65.90%
Market Cap
$1.73B
Gross Margin
49.52%
TTM Avg
50.81%
3Y Avg
52.12%
5Y Avg
52.25%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Astrana Health, Inc. (ASTH) | $1.85B | 9.22% | 9.75% | 12.58% | 13.52% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.86B | 78.67% | 83.63% | 79.97% | 53.31% |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.84B | 72.90% | 70.08% | 67.68% | 66.96% |
| Absci Corporation (ABSI)vs › | $1.87B | -319.36% | -798.46% | -813.46% | -704.28% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 64.48% | 64.91% | 63.02% | 55.66% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.78B | 76.47% | 79.35% | 79.86% | 39.87% |
| Generate Biomedicines, Inc. (GENB)vs › | $1.75B | 100.00% | 100.00% | 100.00% | 100.00% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.95B | 70.49% | 67.64% | 66.50% | 65.90% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.73B | 49.52% | 50.81% | 52.12% | 52.25% |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.71B | 12.55% | 11.67% | 11.80% | 12.59% |
Gross Margin
9.2%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 10.70% |
| 2026-03-31 | 9.35% |
| 2025-12-31 | 8.27% |
| 2025-09-30 | 8.53% |
| 2025-06-30 | 11.91% |
| 2025-03-31 | 11.50% |
| 2024-12-31 | 9.47% |
| 2024-09-30 | 15.35% |
| 2024-06-30 | 13.58% |
| 2024-03-31 | 17.03% |
| 2023-12-31 | 11.04% |
| 2023-09-30 | 20.91% |
| 2023-06-30 | 15.89% |
| 2023-03-31 | 14.19% |
| 2022-12-31 | 13.97% |
| 2022-09-30 | 24.05% |
| 2022-06-30 | 14.69% |
| 2022-03-31 | 16.15% |
| 2021-12-31 | 11.92% |
| 2021-09-30 | 35.07% |
| 2021-06-30 | 22.45% |
